한글목차

경구 혈당 강하제 시장 규모는 최근 꾸준히 성장하고 있습니다. 2025년 595억 7,000만 달러에서 2026년에는 624억 8,000만 달러에 이르고, CAGR 4.9%의 성장이 전망됩니다. 지난 몇 년간의 성장은 전 세계 당뇨병 유병률 증가, 메트포르민의 광범위한 사용, 제네릭 의약품의 보급 확대, 당뇨병 검진 증가, 병원 약국 유통의 성장에 기인하는 것으로 보입니다.

경구 혈당 강하제 시장 규모는 향후 몇 년간도 꾸준한 성장이 전망됩니다. 2030년에는 756억 2,000만 달러에 이르고, CAGR은 4.9%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 생활습관병 관련 당뇨병 환자 증가, 신흥 경제국 수요 증가, 경구용 의약품의 발전, 예방적 당뇨병 치료의 확대, 장기적인 당뇨병 관리 프로그램의 성장 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 복합경구요법 도입 증가, 메트포르민 계열 치료제의 보급 확대, 2형 당뇨병의 조기 관리에 대한 관심 증가, 서방형 경구용 제제의 확대, 비용 효율적인 당뇨병 치료제에 대한 수요 증가 등을 들 수 있습니다.

향후 몇 년 동안 2형 당뇨병 유병률 증가가 경구용 혈당강하제 시장의 성장을 견인할 것으로 예측됩니다. 2형 당뇨병은 신체가 인슐린을 효과적으로 이용하지 못해 혈당 수치가 상승하는 만성 대사 질환입니다. 신체활동의 감소와 비만과 인슐린 저항성의 원인이 되는 좌식 생활습관으로 인해 그 유병률은 증가하는 추세입니다. 경구용 혈당강하제는 인슐린 감수성 개선, 인슐린 분비 촉진 또는 포도당 흡수 억제 등의 작용기전을 통해 혈당을 낮춰 2형 당뇨병 관리에 도움을 줍니다. 예를 들어, 2025년 4월 벨기에에 본부를 둔 비영리단체인 국제당뇨병연맹(IDF)이 발표한 보고서에 따르면, 전 세계 20세에서 79세 사이의 성인 중 약 5억 8,900만 명이 당뇨병을 앓고 있으며, 이 숫자는 2050년까지 8억 5,300만 명에 달할 것으로 예측되고 있습니다. 이에 따라 2형 당뇨병 유병률 증가가 경구용 혈당강하제 시장의 성장을 견인하고 있습니다.

경구용 혈당강하제 시장의 주요 기업들은 혈당 조절을 개선하고 당뇨병 관련 합병증을 줄이기 위해 나트륨 포도당 공수송체 2 억제제(SGLT2 억제제)와 같은 혁신적인 제품 개발에 주력하고 있습니다. SGLT2 억제제는 신장의 포도당 재흡수를 억제하여 과도한 포도당을 소변으로 배설시켜 혈당을 낮추는 경구용 약물의 일종입니다. 이 작용기전은 2형 당뇨병 환자의 혈당 조절 개선, 체중 감소, 심장 및 신장 합병증 위험 감소에 기여합니다. 예를 들어, 2024년 6월 영국에 본사를 둔 바이오 제약사 아스트라제네카(AstraZeneca)는 10세 이상 소아 2형 당뇨병 치료를 위한 경구용 SGLT2 억제제 팔uxiga(다파글리플로진)에 대해 미국 식품의약국(FDA)의 승인을 획득했습니다. 이번 승인에는 1일 1회 경구 투여, 소아 임상시험에서 입증된 안전성 및 유효성, 동급 최초의 작용기전 등이 포함됐습니다. 팔시가는 치료 접근성을 높이고, 장기적인 혈당 조절을 지원하며, 경구용 혈당강하제 시장에서 치료 옵션을 확대할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Oral hypoglycemic agents (OHAs) are medications taken orally to help lower blood glucose levels in individuals with type 2 diabetes mellitus. These drugs work through various mechanisms, including stimulating insulin secretion, enhancing insulin sensitivity, reducing glucose absorption in the gut, or decreasing glucose production by the liver. OHAs are typically prescribed when lifestyle modifications, such as diet and exercise, are insufficient to maintain blood sugar control.

The main types of oral hypoglycemic agents include sulfonylureas, metformin, thiazolidinediones, alpha-glucosidase inhibitors, and immunotherapy. Sulfonylureas are a class of OHAs that stimulate the pancreas to release insulin by acting on beta cells, helping to lower blood glucose levels in type 2 diabetes patients. These agents are available in oral tablets, oral liquids, extended-release formulations, and combination therapy forms. They are used in patients with type 2 diabetes, pre-diabetes, obesity or overweight, and those with multiple comorbidities. OHAs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and nursing homes or long-term care facilities, with end-users including hospitals and clinics.

Tariffs have impacted the oral hypoglycemic agents market by increasing the cost of imported APIs and pharmaceutical intermediates used in diabetes drug manufacturing. These impacts are most pronounced in generic drug manufacturing hubs across Asia Pacific and Europe, where large scale production depends on cross border sourcing. Rising tariff related expenses have placed pressure on drug pricing and manufacturing margins. This has influenced procurement planning and competitive dynamics in both domestic and export markets. However, tariffs have encouraged domestic API production, localized sourcing strategies, and improved long term supply chain resilience.

The oral hypoglycemic agents market research report is one of a series of new reports from The Business Research Company that provides oral hypoglycemic agents market statistics, including oral hypoglycemic agents industry global market size, regional shares, competitors with a oral hypoglycemic agents market share, detailed oral hypoglycemic agents market segments, market trends and opportunities, and any further data you may need to thrive in the oral hypoglycemic agents industry. This oral hypoglycemic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral hypoglycemic agents market size has grown steadily in recent years. It will grow from $59.57 billion in 2025 to $62.48 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rising global diabetes prevalence, widespread use of metformin, expansion of generic drug availability, increased diabetes screening, growth of hospital pharmacy distribution.

The oral hypoglycemic agents market size is expected to see steady growth in the next few years. It will grow to $75.62 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing lifestyle-related diabetes cases, rising demand in emerging economies, advancements in oral drug formulations, expansion of preventive diabetes care, growth of long-term diabetes management programs. Major trends in the forecast period include increasing adoption of combination oral therapies, growing use of metformin-based regimens, rising focus on early type 2 diabetes management, expansion of extended-release oral formulations, increasing demand for cost-effective diabetes drugs.

The increasing prevalence of type 2 diabetes is expected to drive the growth of the oral hypoglycemic agents market in the coming years. Type 2 diabetes is a chronic metabolic disorder in which the body does not use insulin effectively, resulting in elevated blood glucose levels. Its prevalence is rising due to sedentary lifestyles, which reduce physical activity and contribute to obesity and insulin resistance. Oral hypoglycemic agents help manage type 2 diabetes by lowering blood glucose levels through mechanisms such as improving insulin sensitivity, stimulating insulin secretion, or reducing glucose absorption. For example, in April 2025, the International Diabetes Federation (IDF), a Belgium-based non-profit organization, reported that nearly 589 million adults aged 20-79 were living with diabetes worldwide, with this number projected to rise to 853 million by 2050. Consequently, the growing incidence of type 2 diabetes is fueling the oral hypoglycemic agents market.

Leading companies in the oral hypoglycemic agents market are focusing on developing innovative products, such as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), to enhance glycemic control and reduce diabetes-related complications. SGLT2 inhibitors are a class of oral medications that lower blood glucose by preventing the kidneys from reabsorbing glucose, causing excess glucose to be excreted in the urine. This mechanism helps improve glycemic control, reduce body weight, and lower the risk of heart and kidney complications in patients with type 2 diabetes. For example, in June 2024, AstraZeneca plc, a UK-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Farxiga (dapagliflozin), an oral SGLT2 inhibitor designed for the treatment of pediatric type 2 diabetes in patients aged 10 years and older. The approval includes once-daily oral dosing, demonstrated safety and efficacy in pediatric clinical trials, and a first-in-class mechanism of action. Farxiga enhances treatment accessibility, supports better long-term glycemic control, and expands therapeutic options within the oral hypoglycemic agents market.

In July 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche aims to enhance its presence in the obesity and diabetes treatment market by expanding its pipeline of advanced incretin-based therapies. Carmot Therapeutics Inc. is a U.S.-based company focused on developing incretin-based therapies for obesity, diabetes, and related metabolic disorders.

Major companies operating in the oral hypoglycemic agents market are Merck Sharp & Dohme Corp., AstraZeneca plc, Boehringer Ingelheim Ltd., Takeda Pharmaceuticals Limited, Bayer AG, Pfizer Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Huadong Medicine Co. Ltd., Wanbang Biopharmaceuticals Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Biocon Limited

North America was the largest region in the oral hypoglycemic agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral hypoglycemic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral hypoglycemic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral hypoglycemic agents market consists of sales of DPP-4 inhibitors, alpha-glucosidase inhibitors, biguanides, and thiazolidinediones (TZDs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Hypoglycemic Agents Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oral hypoglycemic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral hypoglycemic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral hypoglycemic agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Sulfonylureas; Metformin; Thiazolidinediones; Alpha-Glucosidase Inhibitors
• 2) By Administration Route: Oral Tablets; Oral Liquids; Extended-Release Formulations; Combination Therapy Formulations
• 3) By Patient Type: Type 2 Diabetes Mellitus Patients; Pre-diabetic Patients; Obese Or Overweight Patients; Patients with Multiple Comorbidities
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Nursing Homes and Long-Term Care Facilities
• 5) By End Users: Hospitals; Clinics
• Subsegments:
• 1) By Sulfonylureas: Glipizide; Glyburide; Glimepiride; Chlorpropamide; Tolbutamide
• 2) By Metformin: Immediate-Release Metformin; Extended-Release Metformin (XR); Combination Metformin
• 3) By Thiazolidinediones (TZDs): Pioglitazone; Rosiglitazone
• 4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol; Voglibose
• Companies Mentioned: Merck Sharp & Dohme Corp.; AstraZeneca plc; Boehringer Ingelheim Ltd.; Takeda Pharmaceuticals Limited; Bayer AG; Pfizer Inc.; Novartis AG; Sanofi S.A.; Eli Lilly and Company; Astellas Pharma Inc.; Sun Pharmaceutical Industries Ltd.; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Lupin Limited; Torrent Pharmaceuticals Ltd.; Zydus Lifesciences Ltd.; Huadong Medicine Co. Ltd.; Wanbang Biopharmaceuticals Co. Ltd.; Tonghua Dongbao Pharmaceutical Co. Ltd.; Biocon Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Oral Hypoglycemic Agents Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Oral Hypoglycemic Agents Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Oral Hypoglycemic Agents Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Oral Hypoglycemic Agents Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Combination Oral Therapies
  • 4.2.2 Growing Use Of Metformin-Based Regimens
  • 4.2.3 Rising Focus On Early Type 2 Diabetes Management
  • 4.2.4 Expansion Of Extended-Release Oral Formulations
  • 4.2.5 Increasing Demand For Cost-Effective Diabetes Drugs

5. Oral Hypoglycemic Agents Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Long-Term Care Facilities
• 5.4 Retail Pharmacies
• 5.5 Homecare Settings

6. Oral Hypoglycemic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oral Hypoglycemic Agents Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Oral Hypoglycemic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Oral Hypoglycemic Agents Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Oral Hypoglycemic Agents Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Oral Hypoglycemic Agents Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oral Hypoglycemic Agents Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oral Hypoglycemic Agents Market Segmentation

• 9.1. Global Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors
• 9.2. Global Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral Tablets, Oral Liquids, Extended-Release Formulations, Combination Therapy Formulations
• 9.3. Global Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Type 2 Diabetes Mellitus Patients, Pre-diabetic Patients, Obese Or Overweight Patients, Patients with Multiple Comorbidities
• 9.4. Global Oral Hypoglycemic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Nursing Homes and Long-Term Care Facilities
• 9.5. Global Oral Hypoglycemic Agents Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics
• 9.6. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide
• 9.7. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immediate-Release Metformin, Extended-Release Metformin (XR), Combination Metformin
• 9.8. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Thiazolidinediones (TZDs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pioglitazone, Rosiglitazone
• 9.9. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Acarbose, Miglitol, Voglibose

10. Oral Hypoglycemic Agents Market Regional And Country Analysis

• 10.1. Global Oral Hypoglycemic Agents Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Oral Hypoglycemic Agents Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oral Hypoglycemic Agents Market

• 11.1. Asia-Pacific Oral Hypoglycemic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oral Hypoglycemic Agents Market

• 12.1. China Oral Hypoglycemic Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oral Hypoglycemic Agents Market

• 13.1. India Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oral Hypoglycemic Agents Market

• 14.1. Japan Oral Hypoglycemic Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oral Hypoglycemic Agents Market

• 15.1. Australia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oral Hypoglycemic Agents Market

• 16.1. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oral Hypoglycemic Agents Market

• 17.1. South Korea Oral Hypoglycemic Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oral Hypoglycemic Agents Market

• 18.1. Taiwan Oral Hypoglycemic Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oral Hypoglycemic Agents Market

• 19.1. South East Asia Oral Hypoglycemic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oral Hypoglycemic Agents Market

• 20.1. Western Europe Oral Hypoglycemic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oral Hypoglycemic Agents Market

• 21.1. UK Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oral Hypoglycemic Agents Market

• 22.1. Germany Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oral Hypoglycemic Agents Market

• 23.1. France Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oral Hypoglycemic Agents Market

• 24.1. Italy Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oral Hypoglycemic Agents Market

• 25.1. Spain Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oral Hypoglycemic Agents Market

• 26.1. Eastern Europe Oral Hypoglycemic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oral Hypoglycemic Agents Market

• 27.1. Russia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oral Hypoglycemic Agents Market

• 28.1. North America Oral Hypoglycemic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oral Hypoglycemic Agents Market

• 29.1. USA Oral Hypoglycemic Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oral Hypoglycemic Agents Market

• 30.1. Canada Oral Hypoglycemic Agents Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oral Hypoglycemic Agents Market

• 31.1. South America Oral Hypoglycemic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oral Hypoglycemic Agents Market

• 32.1. Brazil Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oral Hypoglycemic Agents Market

• 33.1. Middle East Oral Hypoglycemic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oral Hypoglycemic Agents Market

• 34.1. Africa Oral Hypoglycemic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Oral Hypoglycemic Agents Market, Segmentation By Product Type, Segmentation By Administration Route, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oral Hypoglycemic Agents Market Regulatory and Investment Landscape

36. Oral Hypoglycemic Agents Market Competitive Landscape And Company Profiles

• 36.1. Oral Hypoglycemic Agents Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Oral Hypoglycemic Agents Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Oral Hypoglycemic Agents Market Company Profiles
  • 36.3.1. Merck Sharp & Dohme Corp. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Boehringer Ingelheim Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Takeda Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Oral Hypoglycemic Agents Market Other Major And Innovative Companies

• Pfizer Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Huadong Medicine Co. Ltd., Wanbang Biopharmaceuticals Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Biocon Limited

38. Global Oral Hypoglycemic Agents Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oral Hypoglycemic Agents Market

40. Oral Hypoglycemic Agents Market High Potential Countries, Segments and Strategies

• 40.1 Oral Hypoglycemic Agents Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Oral Hypoglycemic Agents Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Oral Hypoglycemic Agents Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer